| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07198074 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin… |
Trial sites expanded: 206 -> 211 locations |
| 2026-06-12 | NCT07061977 Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation… |
Trial sites expanded: 253 -> 260 locations |
| 2026-06-12 | NCT05112601 Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR)… |
date change Primary completion pushed: 2026-04-30 -> 2032-07-30 |
| 2026-06-12 | NCT05112601 Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR)… |
date change Completion pushed: 2026-04-30 -> 2032-07-30 |
| 2026-06-12 | NCT03854474 Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475)… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT03854474 Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475)… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Recruitment opened |
| 2026-06-12 | NCT07383441 Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer |
Trial sites expanded: 0 -> 41 locations |
| 2026-06-12 | NCT07152821 Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory… |
Trial sites expanded: 22 -> 55 locations |
| 2026-06-12 | NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… |
Trial terminated |
| 2026-06-12 | NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… |
date change Primary completion moved earlier: 2027-07-15 -> 2026-05-15 |
| 2026-06-12 | NCT06984328 Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to… |
date change Completion moved earlier: 2029-07-15 -> 2026-05-15 |
| 2026-06-12 | NCT06666348 Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated… |
Trial sites expanded: 5 -> 8 locations |
| 2026-06-12 | NCT05111574 Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-11 | NCT04603248 A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent… |
Trial completed |
| 2026-06-11 | NCT04603248 A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent… |
date change Primary completion moved earlier: 2026-09 -> 2026-03-18 |
| 2026-06-11 | NCT04603248 A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent… |
date change Completion moved earlier: 2026-09 -> 2026-03-18 |
| 2026-06-11 | NCT05929664 Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell… |
Recruitment suspended |
| 2026-06-11 | NCT05317000 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC |
Trial arms changed: 3 -> 2 |
| 2026-06-11 | NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's… |
Trial sites expanded: 339 -> 350 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-10 | NCT07639242 Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… | Phase 2 | Not Yet Recruiting |
| 2026-06-09 | NCT07636863 Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig | Completed | |
| 2026-06-08 | NCT07631325 Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable… | Phase 1/2 | Not Yet Recruiting |
| 2026-06-08 | NCT07634094 Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and… | Phase 2 | Not Yet Recruiting |
| 2026-06-08 | NCT07634380 Sitagliptin With Pembro in RCC and Melanoma | Phase 1 | Not Yet Recruiting |
| 2026-06-05 | NCT07629700 Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With… | Not Yet Recruiting | |
| 2026-06-03 | NCT07622186 A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer… | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07619599 A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among… | Phase 1 | Not Yet Recruiting |
| 2026-06-02 | NCT07620548 Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in… | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally… | Locally Advanced Bladder Urothelial Carcinoma | Recruiting |
| NCT06831370 | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults… | Hodgkin Lymphoma | Recruiting |
| NCT06031233 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | Oncology | Recruiting |
| NCT07504796 | ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab | Metastatic Melanoma | Recruiting |
| NCT05689671 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… | Non-Small Cell Lung Cancer Metastatic | Active, Not Recruiting |
| Phase 3 | |||
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in… | Non-small Cell Lung Cancer | Recruiting |
| NCT06908304 | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in… | Carcinoma, Non-Small -Cell Lung | Recruiting |
| NCT07315750 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus… | Gastric Carcinoma | Recruiting |
| NCT07362459 | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in… | Non-Small Cell Lung Carcinoma (NSCLC) | Recruiting |
| NCT04339218 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in… | Lung Adenocarcinoma | Recruiting |
| NCT06711900 | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma… | Advanced Melanoma | Recruiting |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for… | Gastroesophageal-junction Cancer | Recruiting |
| NCT07026474 | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally… | Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic… | Gastric Cancer | Recruiting |
| NCT05317858 | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care… | Brain Tumor | Recruiting |
| NCT06758401 | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric… | Gastric Cancer | Recruiting |
| NCT06103864 | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's… | Breast Cancer | Recruiting |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus… | Glioblastoma | Recruiting |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients… | Advanced Hepatocellular Carcinoma | Recruiting |
| NCT06246916 | A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants… | Melanoma | Recruiting |
| NCT06989112 | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or… | Endometrial Cancer | Recruiting |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced… | Advanced Esophageal Adenocarcinoma | Recruiting |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care… | Biliary Tract Cancer | Recruiting |